Undervalued Medical Diagnostic & Research Stocks on NYS June 2025

June 28, 2025

Medical Diagnostics & Research

Medical Diagnostics & Research companies provide laboratory testing services through imaging and other diagnostic services to the medical industry.

New York Stock Exchange

The New York Stock Exchange, located in New York City, is the largest securities exchange in the world by market capitalization of its listed companies.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Medical Diagnostics & Research stocks

Stocks in this category are held primarily for potential income and capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
TMO Thermo Fisher Scientific 402.82 456.58 13.35 2768877 152669 0.40 23.6
IQV IQVIA Hldgs 140.33 155.29 10.66 2696135 24895 0.00 19.1
DHR Danaher 189.90 209.39 10.26 3874440 136880 0.60 36.8
A Agilent Technologies 111.92 119.04 6.37 2298842 31897 0.86 27.6
WAT Waters 349.24 351.05 0.52 565700 20853 0.00 31.7
All data provided as at market close May 29, 2025.

Company Details

Thermo Fisher Scientific

TMO:NYS

Close Price

402.82

Our Valuation

456.58

% Difference

13.35

Market Cap ($M)

152669

P/E Ratio

23.6

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).

Access the stockcalc valuation


IQVIA Hldgs

IQV:NYS

Close Price

140.33

Our Valuation

155.29

% Difference

10.66

Market Cap ($M)

24895

P/E Ratio

19.1

Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms.

Access the stockcalc valuation


Danaher

DHR:NYS

Close Price

189.90

Our Valuation

209.39

% Difference

10.26

Market Cap ($M)

136880

P/E Ratio

36.8

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.

Access the stockcalc valuation


Agilent Technologies

A:NYS

Close Price

111.92

Our Valuation

119.04

% Difference

6.37

Market Cap ($M)

31897

P/E Ratio

27.6

Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Waters

WAT:NYS

Close Price

349.24

Our Valuation

351.05

% Difference

0.52

Market Cap ($M)

20853

P/E Ratio

31.7

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions.

Access the stockcalc valuation


Thermo Fisher Scientific and IQVIA Hldgs are the most undervalued Medical Diagnostics & Research stocks on the NYS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-medical-diagnostic-research-stocks-nys-june-2025
Thermo Fisher Scientific $TMO and IQVIA Hldgs $IQV are the most undervalued Medical Diagnostics & Research stocks on the #NYS. See the full list: https://www.stockcalc.com/Blog/undervalued-medical-diagnostic-research-stocks-nys-june-2025
Thermo Fisher Scientific and IQVIA Hldgs are the most undervalued Medical Diagnostics & Research stocks on the NYS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-medical-diagnostic-research-stocks-nys-june-2025

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.